CPRX
CATALYST PHARMACEUTICALS, INC.
$31.28
+0.03%
$3.8B
No data for this timeframe.
Vol
Market Cap$3.8B
Cap SizeMid Cap
Analyst ConsensusBuy (50%)
Inst. Holders7 funds
Inst. Value$421.9M
Inst. Activity2 buys / 1 sells
SEC Reports8
Recent Activity
Jun 3, 2026
Insider
Andrews William T. sold 743 shares
Chief Medical Officer @ $0.00 ($0.00)
Jun 3, 2026
Insider
Andrews William T. sold 3,052 shares
Chief Medical Officer @ $0.00 ($0.00)
May 28, 2026
SEC
Catalyst Pharmaceuticals (CPRX) filed a preliminary proxy statement (PREM14A) seeking stockholder approval for its acqui
PREM14A — Impact 8/10
May 22, 2026
short_volume
Short Volume: CPRX — 57.7% short (0.5M / 0.9M)
Short: 547,770 | Exempt: 3,606 | TRF Vol: 949,595 | Short Ratio: 57.7% | Off-exchange volume (dark p
May 12, 2026
SEC
Catalyst Pharmaceuticals filed additional definitive proxy soliciting materials (DEFA14A) containing an employee update
DEFA14A — Impact 3/10
May 11, 2026
SEC
Catalyst Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.50 on total revenue of $149.4M, missing the consensus e
PRESS-RELEASE — Impact 8/10
Feb 17, 2026
Insider
Russo Gregg sold 687 shares
Chief HR Officer @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — ADD
2,933,399 shares ($68.5M)
Price Targets
$32.60
+4.0% upside
Hold
Current $31.34
Low $31.50
Median $32.00
High $36.00
5 analysts
$31.50
$36.00
Analyst Ratings
2Strong Buy
4Buy
6Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| May 8, 2026 | Citigroup | DOWNGRADE | Buy → Neutral |
| May 7, 2026 | Stephens & Co. | DOWNGRADE | Overweight → Equal-Weight |
| Mar 3, 2026 | Citigroup | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.69 ▲ +2.6% | $0.65 — $0.72 | 2% YoY | 4 |
| Next Q | $0.73 ▲ +2.1% | $0.69 — $0.78 | 7% YoY | 4 |
| Current FY | $2.86 | $2.79 — $2.96 | 5% YoY | 4 |
| Next FY | $3.14 ▲ +0.6% | $2.44 — $3.55 | 10% YoY | 4 |
Latest Reports
BULLISH
PREM14A
8/10
Catalyst Pharmaceuticals (CPRX) filed a preliminary proxy statement (PREM14A) seeking stockholder approval for its acqui
May 28, 2026
NEUTRAL
DEFA14A
3/10
Catalyst Pharmaceuticals filed additional definitive proxy soliciting materials (DEFA14A) containing an employee update
May 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $196.8M | — |
| MORGAN STANLEY | $68.5M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $61.9M | TRIM |
| BANK OF AMERICA CORP | $51.3M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $31.7M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Andrews William | F | $0.00 |
| Jun 3, 2026 | Andrews William | M | $0.00 |
| Feb 17, 2026 | Russo Gregg | M | $0.00 |
| Feb 17, 2026 | Russo Gregg | F | $0.00 |
| Feb 17, 2026 | Russo Gregg | M | $0.00 |
7 institutional holders with $421.9M total value (18,074,503 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 8,432,247 | $196.8M | 46.7% | — |
| 2 | MORGAN STANLEY | 2,933,399 | $68.5M | 16.2% | ADD +59.1% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 2,650,077 | $61.9M | 14.7% | TRIM -25.2% |
| 4 | BANK OF AMERICA CORP /DE/ | 2,199,842 | $51.3M | 12.2% | ADD +30.6% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,356,499 | $31.7M | 7.5% | NEW |
| 6 | FMR LLC | 343,737 | $8.0M | 1.9% | TRIM -28.9% |
| 7 | WELLS FARGO & COMPANY/MN | 158,702 | $3.7M | 0.9% | ADD +37.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 1,843,624 | 2,933,399 | +59.1% | $68.5M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 3,544,830 | 2,650,077 | -25.2% | $61.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 115,084 | 158,702 | +37.9% | $3.7M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 3,183,523 | 1,843,624 | -42.1% | $36.3M | 2025-Q3 |
| UBS Group AG | TRIM | 844,777 | 593,609 | -29.7% | $11.7M | 2025-Q3 |
| FMR LLC | TRIM | 509,113 | 362,217 | -28.9% | $7.1M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 163,715 | 115,084 | -29.7% | $2.3M | 2025-Q3 |
| NORGES BANK | EXIT | 13,766 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 2,394,555 | 3,183,523 | +32.9% | $69.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,811,475 | 2,365,675 | +30.6% | $51.3M | 2025-Q2 |
| FMR LLC | ADD | 319,879 | 509,113 | +59.2% | $11.0M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 97,395 | 163,715 | +68.1% | $3.6M | 2025-Q2 |
| NORGES BANK | NEW | — | 13,766 | — | $298.7K | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 461,567 | 716,016 | +55.1% | $17.4M | 2025-Q1 |
| FMR LLC | DOUBLED | 112,482 | 319,879 | +184.4% | $7.8M | 2025-Q1 |
| NORGES BANK | EXIT | 91,770 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 212,845 | 722,858 | +239.6% | $15.1M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 48,338 | 461,567 | +854.9% | $9.6M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 155,931 | 82,820 | -46.9% | $1.7M | 2024-Q4 |
| MORGAN STANLEY | ADD | 1,012,679 | 1,823,274 | +80.0% | $36.2M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,167,743 | — | $23.2M | 2024-Q3 |
2 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Andrews William T. | Chief Medical Officer | F | 743 | $0.00 | $0.00 |
| Jun 3, 2026 | Andrews William T. | Chief Medical Officer | M | 3,052 | $0.00 | $0.00 |
| Feb 17, 2026 | Russo Gregg | Chief HR Officer | M | 687 | $0.00 | $0.00 |
| Feb 17, 2026 | Russo Gregg | Chief HR Officer | F | 211 | $0.00 | $0.00 |
| Feb 17, 2026 | Russo Gregg | Chief HR Officer | M | 687 | $0.00 | $0.00 |
| Jun 3, 2025 | Andrews William T. | Chief Medical Officer | M | 3,052 | $0.00 | $0.00 |
8 SEC filing reports analyzed. Sentiment: 5 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 7.0/10.
BULLISH
PREM14A
8/10
Catalyst Pharmaceuticals (CPRX) filed a preliminary proxy statement (PREM14A) seeking stockholder ap
May 28, 2026
NEUTRAL
DEFA14A
3/10
Catalyst Pharmaceuticals filed additional definitive proxy soliciting materials (DEFA14A) containing
May 12, 2026
BEARISH
PRESS-RELEASE
8/10
Catalyst Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.50 on total revenue of $149.4M, mis
May 11, 2026
BULLISH
DEFA14A
8/10
Catalyst Pharmaceuticals (CPRX) filed additional proxy soliciting materials for its pending acquisit
May 7, 2026
BULLISH
DEFA14A
8/10
Catalyst Pharmaceuticals has entered into a definitive agreement to be acquired by Angelini Pharma S
May 7, 2026
BULLISH
8-K
9/10
Catalyst Pharmaceuticals (CPRX) has entered into a definitive agreement to be acquired by Angelini P
May 7, 2026
NEUTRAL
8-K/A
4/10
Catalyst Pharmaceuticals filed an amended 8-K to correct a scrivener's error in the signature date o
Mar 19, 2026
BULLISH
8-K
8/10
Catalyst Pharmaceuticals reported record financial results for Q4 and full year 2025, with total rev
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (50% buy). Based on 12 analysts: 2 strong buy, 4 buy, 6 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$32.60 mean target
+4.0% upside
Hold (2.67)
$31.50 Low
$36.00 High
| Metric | Value |
|---|---|
| Current Price | $31.34 |
| Target Low | $31.50 |
| Target Mean | $32.60 |
| Target Median | $32.00 |
| Target High | $36.00 |
| # Analysts | 5 |
| Recommendation | Hold (2.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.69 | $0.65 | $0.72 | 1.8% | +2.6% | 1↑ 0↓ | $0.2B | 5.0% | 4 |
| Next Q 2026-09-30 |
$0.73 | $0.69 | $0.78 | 7.4% | +2.1% | 1↑ 0↓ | $0.2B | 8.3% | 4 |
| Current FY 2026-12-31 |
$2.86 | $2.79 | $2.96 | 5.1% | +0.3% | 1↑ 0↓ | $0.6B | 6.9% | 4 |
| Next FY 2027-12-31 |
$3.14 | $2.44 | $3.55 | 9.7% | +0.6% | 1↑ 0↓ | $0.7B | 11.5% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.692 | |
| 7d ago | $0.692 | |
| 30d ago | $0.675 | +0.018 |
| 60d ago | $0.675 | +0.018 |
| 90d ago | $0.632 | +0.060 |
3 analyst firms have rated this stock: 0 upgrades, 3 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| May 8, 2026 | Citigroup | DOWNGRADE | Buy | Neutral |
| May 7, 2026 | Stephens & Co. | DOWNGRADE | Overweight | Equal-Weight |
| Mar 3, 2026 | Citigroup | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 6 | 0 | 0 | 50% | |
| May 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 22, 2026
short_volume
Short Volume: CPRX — 57.7% short (0.5M / 0.9M)
Short: 547,770 | Exempt: 3,606 | TRF Vol: 949,595 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: CPRX — 55.9% short (0.6M / 1.1M)
Short: 601,881 | Exempt: 14,682 | TRF Vol: 1,076,356 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: CPRX — 64.8% short (1.0M / 1.5M)
Short: 969,541 | Exempt: 303 | TRF Vol: 1,496,245 | Short Ratio: 64.8% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: CPRX — 64.2% short (1.0M / 1.5M)
Short: 989,351 | Exempt: 6,417 | TRF Vol: 1,540,016 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
CPRX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
<p align="center"><em>Delivered Q1 2026 Total Revenues </em><em>of $149.4 Million</em><br><em>Results include 28% YoY Increase in Net Product Revenues
May 7, 2026
earnings
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
The Company will Report First Quarter 2026 Financial Results on May 11, 2026 <pre>The Company will Report First Quarter 2026 Financial Results on May
May 7, 2026
other
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
<p align="center"><em>As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035</em></p>
May 5, 2026
earnings_calendar
CPRX Q1 2026 Earnings Scheduled — 2026-05-05
Apr 30, 2026
short_interest
FTD: CPRX — 98,833 shares ($2.8M) failed to deliver
Settlement: 20260430, Price: $28.26, FTD Value: $2,793,020.58, CATALYST PHARMACEUTICALS INC.
Apr 28, 2026
earnings
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET <pre>The Company will Host a Conference Call and Webcast on May 12,
Apr 20, 2026
short_interest
FTD: CPRX — 453,627 shares ($11.9M) failed to deliver
Settlement: 20260420, Price: $26.26, FTD Value: $11,912,245.02, CATALYST PHARMACEUTICALS INC.
Mar 17, 2026
short_interest
FTD: CPRX — 51,438 shares ($1.2M) failed to deliver
Settlement: 20260317, Price: $23.30, FTD Value: $1,198,505.4, CATALYST PHARMACEUTICALS INC.
Mar 6, 2026
other
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
<p align="justify">CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-s
Feb 25, 2026
earnings_calendar
CPRX Q4 2025 Earnings After Market Close — 2026-02-25